BLOOD AND BLOOD COMPONENTS

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Part 12 and as supplemented with additional information included in this notice. This solicitation is issued as a Request for Quotation (RFQ), solicitation number 36C25026Q0638, in accordance with FAR Part 12. This announcement constitutes the only solicitation; QUOTES ARE BEING REQUESTED and a written solicitation will not be issued. Awards resulting from the (RFQ) will be based on Best Value to the Department of Veterans Affairs giving consideration to: Technical Capability, Past Performance, Price. This acquisition is Unrestricted, the North American Industry Classification System (NAICS) code is 621991 and has a size standard of $40 million dollars. The solicitation incorporates provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2025-007, effective March 13, 2026. The Government will issue a Firm Fixed Price, Indefinite Delivery/Indefinite Quantity Contract. STATEMENT OF WORK (SOW) Background: The Department of Veterans Affairs Network Contracting Office (NCO) 10, Louis Stokes Cleveland Veterans Affairs Medical Center (CLE VAMC), Pathology and Laboratory Medicine Service (PLMS) requires a reliable, continuous, and regulatory-compliant supply of blood and blood components to support inpatient and outpatient clinical services. Blood and blood components are mission-critical biological products required to sustain hospital operations and direct patient care, including but not limited to: Emergency trauma resuscitation. Surgical and perioperative services. Oncology and chemotherapy support. Hematology and transfusion therapy. Intensive care and critical care management. Cardiovascular and gastrointestinal procedures. Management of anemia, coagulopathies, and massive transfusion protocols. There is no substitute for human blood and blood components in transfusion medicine. These biological products cannot be synthetically manufactured and must be collected, tested, processed, and distributed under strict federal regulatory oversight. Any interruption in supply would immediately jeopardize patient safety, halt surgical services, compromise trauma response capability, delay oncology treatments, and place transfusion-dependent patients at significant clinical risk. Failure to maintain a continuous and compliant blood supply would also place CLE VAMC at risk of regulatory noncompliance under Food and Drug Administration (FDA), American Association of Blood Banks (AABB), Joint Commission, and Veterans Health Administration (VHA) standards. Due to stringent federal qualification criteria, FDA licensure requirements, donor screening standards, interstate shipment authorizations, and biologics regulatory oversight associated with blood collection and distribution, this requirement necessitates procurement from a qualified and properly licensed blood supplier. The Government intends to award an Indefinite Delivery, Indefinite Quantity (IDIQ) contract consisting of a Base Year plus four (4) Option Years to ensure uninterrupted patient care, regulatory compliance, and operational readiness. This requirement is mission essential and cannot be accomplished without an awarded contract to a qualified blood supplier. Scope: The Contractor shall furnish all labor, materials, testing, processing, packaging, transportation, regulatory compliance, and associated services necessary to supply blood and blood components to CLE VAMC, PLMS. The Contractor shall maintain the operational capability necessary to support routine, urgent, and emergency transfusion requirements, including access to specialty blood products and immunohematology reference services necessary to support patient care operations. The Contractor shall also maintain the capability to support continuity of blood product availability during periods of increased demand, regional shortages, severe weather events, disasters, public health emergencies, or other circumstances that may disrupt normal supply operations. Products shall be supplied in quantities and at times required to support ongoing clinical operations in accordance with all Federal laws, FDA regulations, and contract terms. 3. Specific Tasks: BLOOD PRODUCT SUITABILITY REQUIREMENTS: Testing Requirements: All blood shall: Be tested for ABO and Rh typing. Be screened for unexpected antibodies. Be tested for infectious disease markers in accordance with FDA requirements. Meet all FDA transfusion suitability standards. Collection and Processing: Blood shall be collected using a closed aseptic system. Containers shall be FDA-approved, sterile, and pyrogen-free. Units shall be free of hemolysis, gross chyle, icterus, or clots. Labeling shall comply with FDA and ISBT standards. Red Blood Cells: Low-volume red cells will not be accepted. Each unit shall include: At least one peel-off ISBT number At least two heat-sealed segments Minimum seven (7) days remaining shelf life unless approved by VA Blood Bank personnel. Platelets: Apheresis platelets shall have at least one (1) day remaining shelf life. Same-day expiration units require prior approval. Platelets shall undergo pathogen reduction technology when available. Cold Stored Platelets: Cold stored platelets are platelet blood products stored at refrigerated temperatures, typically between 1–6°C, rather than at standard room temperature conditions used for conventional platelets. These products are specifically utilized in transfusion medicine for patients experiencing active bleeding, trauma, massive transfusion events, emergency surgery, and other critical situations where rapid hemostatic support is required. Cold stored platelets provide enhanced immediate clot-forming capability and are commonly utilized in emergency and surgical settings due to th…